# A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

> **NCT03470922** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 714 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Relatlimab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03470922
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-11
- **Primary completion:** 2021-01-25
- **Final completion:** 2030-12-15
- **Target enrollment:** 714 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03470922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03470922, "A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03470922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*